Cargando…
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877600/ https://www.ncbi.nlm.nih.gov/pubmed/29510588 http://dx.doi.org/10.3390/ijms19030739 |